Figure 6).
Treatment of lamivudine (LAM)-resistant chronic hepatitis B patients, phase III (2009) – Quebec: Public versus private insurance coverage. ADF Adefovir; ETV Entecavir; IFN Standard interferon-alpha; Peg-IFN Pegylated interferon-alpha 2a (Pegasys, Genentech, USA); TDF Tenofovir; Telb Telbivudine